drugset / Trial / NCT01678755
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
RandomizedParallel-groupTriple-blindTreatment
Summary
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
Timeline
- Start
- 2012-08
- Primary completion
- 2014-03
- Completion
- 2014-03
Outcome
Missed primary endpoint
paper No statistical difference in the change from baseline score between any of the ABT-126 dose groups and placebo was observed on the MCCB neurocognitive composite score. PMID 28922590 ↗
paper ABT-126 did not demonstrate a procognitive effect in subjects with stable schizophrenia who smoke. PMID 28922590 ↗
Publications
- Results Haig GM, Wang D, Zhao J, Othman AA, Bain EE. Efficacy and Safety of the alpha7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers. J Clin Psychiatry. 2018 May/Jun;79(3):16m11162. doi: 10.4088/JCP.16m11162.
- Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-126 | Small molecule | 25 mg | — |
| Subject | ABT-126 | Small molecule | 75 mg | — |